Immune checkpoint inhibitors for cancer and venous thromboembolic events

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival

(2021) Tamara A Sussman et al.   Journal for ImmunoTherapy of Cancer

Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis

(2020) Lili Zhang et al.   EUROPEAN HEART JOURNAL

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis

(2020) Magid Awadalla et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis

(2020) Lili Zhang et al.   CIRCULATION

Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque

(2020) Zsofia D. Drobni et al.   CIRCULATION

Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review

(2020) Cinzia Solinas et al.   THROMBOSIS RESEARCH

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors

(2019) Magid Awadalla et al.   Journal for ImmunoTherapy of Cancer

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

(2019) Vicky Makker et al.   LANCET ONCOLOGY

Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study

(2019) Jair Bar et al.   EUROPEAN JOURNAL OF CANCER

Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors

(2019) Yosuke Ando et al.   INVESTIGATIONAL NEW DRUGS

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

(2019) Federico Nichetti et al.   Cancers

Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient

(2018) Yuko Horio et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pembrolizumab-induced acute thrombosis

(2018) Kei Kunimasa et al.   MEDICINE

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety

(2015) Rongxia Li et al.   Journal of Biopharmaceutical Statistics

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Development and validation of a predictive model for chemotherapy-associated thrombosis

(2008) A. A. Khorana et al.   BLOOD